A comparison of drug-seeking behavior maintained by D: -amphetamine, L: -deprenyl (selegiline), and D: -deprenyl under a second-order schedule in squirrel monkeys
by
Yasar S, Gaal J, Panlilio LV, Justinova Z,
Molnar SV, Redhi GH, Schindler CW.
Preclinical Pharmacology Section,
Behavioral Neurosciences Research Branch,
DHHS/NIH/NIDA Intramural Research Program,
Baltimore, MD, 21224, USA.
Psychopharmacology (Berl). 2005 Nov 15;:1-9

ABSTRACT

L: -Deprenyl (selegiline) is used in the treatment of Parkinson's disease and has been proposed as an aid for cigarette smoking cessation and a treatment for psychostimulant abuse. L: -Deprenyl is metabolized in the body to L: -methamphetamine and L: -amphetamine, suggesting that it may have abuse potential. The current study assessed whether L: -deprenyl or its isomer would maintain drug-seeking behavior on a second-order schedule and whether L: -deprenyl would alter drug-seeking behavior maintained by D: -amphetamine if given as a pretreatment. Squirrel monkeys learned to respond on a second-order schedule of reinforcement, where every tenth response was followed by a brief light flash, and the first brief light flash after 30 min was paired with intravenous (i.v.) injection of D: -amphetamine (0.56 mg/kg), administered over a 2-min period at the end of the session. When responding was stable, saline or different i.v. doses of D: -amphetamine (0.3-1.0 mg/kg), L: -deprenyl (0.1-10.0 mg/kg), and D: -deprenyl (0.1-3.0 mg/kg) were substituted for 10 days each. Subsequently, monkeys were pretreated with 0.3 or 1.0 mg/kg L: -deprenyl intramuscularly 30 min prior to D: -amphetamine baseline sessions. D: -Amphetamine maintained high rates of drug-seeking behavior on the second-order schedule. D: -Deprenyl maintained high rates of drug-seeking behavior similar to D: -amphetamine. L: -Deprenyl maintained lower rates of responding that were not significantly above saline substitution levels. Pretreatment with L: -deprenyl failed to alter drug-seeking behavior maintained by D: -amphetamine. These results indicate that D: -deprenyl, but not L: -deprenyl, may have abuse potential. Under conditions where drug-seeking and drug-taking behaviors are actively maintained by D: -amphetamine, L: -deprenyl, at doses that specifically inhibit type B monoamine oxidase, may not be effective as a treatment.

High-dosage
Antidepressant
Phenylethylamine
Antioxidant dosage
Atypical depressives
Long-term high-dosage
Selegiline plus phenylalanine
Selegiline and life-expectancy
Selegiline for longer-lived flies
Selegiline as an immunostimulant
Selegiline for cocaine-dependence
Selegiline and Parkinson's disease
Selegiline, NO and Alzheimer's disease
Antidepressant/dopamine D1 receptors
Transdermal selegiline as an antidepressant
Somerset's new transdermal selegiline patch

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family